Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CLIC-02: A Phase I Trial of CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies

NCT06208735 is registered in ClinicalTrials.gov with British Columbia Cancer Agency as lead sponsor.

NCT NCT06208735
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06208735 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CLIC-02: A Phase I Trial of CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
Lead sponsor
British Columbia Cancer Agency
Phase
Phase 1
Overall status
Recruiting
Start date
January 2, 2025
Completion date
August 1, 2028
Enrollment
24 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell acute lymphoblastic leukemia, b-cell leukemia, b-cell lymphoma, diffuse large b cell lymphoma, high-grade b-cell lymphoma, mantle cell lymphoma, non-hodgkin's lymphoma, primary mediastinal large b-cell lymphoma (pmbcl)